Abstract Details
|
Thomas Brannagan III, MD, FAAN
(Columbia University)
PRESENTER |
Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Grifols. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL. Dr. Brannagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam. The institution of Dr. Brannagan has received research support from Alnylam. The institution of Dr. Brannagan has received research support from Acceleron. The institution of Dr. Brannagan has received research support from Ionis. The institution of Dr. Brannagan has received research support from Pharnext. |
| Annabel K. Wang, MD, FAAN (VA Long Beach Healthcare System) | Dr. Wang has nothing to disclose. |
| Teresa Coelho, MD (Unidate Clinica de Paramoloidose Hospital) | Dr. Coelho has nothing to disclose. |
| Marcia Waddington Cruz, MD (Hospital Universitario) | Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sobi. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Waddington Cruz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. |
| Michael J. Polydefkis, MD, FAAN (Johns Hopkins University School of Medicine) | Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex Pharmaceutical . Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Polydefkis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. |
| Peter J. Dyck, MD, FAAN (Mayo Clinic) | Dr. Dyck has nothing to disclose. |
| No disclosure on file | |
| Violaine Plante-Bordeneuve, MD (CHU Henri Mondor) | Dr. Plante-Bordeneuve has nothing to disclose. |
| John L. Berk | John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ionis Pharmaceuticals. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca/IONIS. John L. Berk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eidos/BridgBio. John L. Berk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Intellia Therapeutics. John L. Berk has received research support from Alnylam . John L. Berk has received research support from Ionis. John L. Berk has received research support from Eidos/Bridgbio. |
| Fabio Adrian Barroso, MD | Fabio Adrian Barroso, MD has nothing to disclose. |
| David D. Adams (APHP) | David D. Adams has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ALNYLAM. David D. Adams has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Isabel Conceicao (Hospital de Santa Maria) | Isabel Conceicao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Isabel Conceicao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sobi. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Josep Gamez, MD, PhD (HOSPITAL UNIVERSITARI VALL D' HEBRON) | The institution of Dr. Gamez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. The institution of Dr. Gamez has received research support from Government of Spain (FIS FEDER). |
| No disclosure on file | |
| Brett Monia, PhD (Ionis Pharmaceuticals) | No disclosure on file |
| Steven hughes | No disclosure on file |
| No disclosure on file | |
| Bradley W. McEvoy | Bradley W. McEvoy has received personal compensation for serving as an employee of Acadia Pharmaceuticals. Bradley W. McEvoy has received stock or an ownership interest from Acadia Pharmaceuticals. |
| Brenda F. Baker | No disclosure on file |
| Elizabeth Ackermann, PhD (ISIS PHARMACEUTICALS, INC) | No disclosure on file |
| Merrill Benson | No disclosure on file |
| No disclosure on file |